Squinting through layers of fog: Assessing the cost effectiveness of treatments for multiple sclerosis

Applied Health Economics and Health Policy

Volumn 11, Issue 4, 2013, Pages 331-341

  Hawton, Annie ^a   Shearer, James ^a   Goodwin, Elizabeth ^a   Green, Colin ^a  

^a UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; PLACEBO;

CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CONCEPTUAL FRAMEWORK; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISABILITY; DISEASE COURSE; ECONOMIC EVALUATION; EPIDEMIOLOGICAL DATA; EXPANDED DISABILITY STATUS SCALE; HEALTH INSURANCE; HEALTH STATE UTILITY VALUE; HUMAN; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PSYCHOMETRY; QUALITY ADJUSTED LIFE YEAR; RATING SCALE; REMISSION; REVIEW; STEM CELL TRANSPLANTATION; SYMPTOM;

COST-BENEFIT ANALYSIS; HUMANS; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84880892136     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-013-0034-0     Document Type: Review

References (85)

1. Zwibel H. Contribution to impaired mobility and general symptoms to the burden of multiple sclerosis. Adv Ther. 2009;26:1043-57.
2. Kobelt G, Berg J, Atherly D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006;66:1696-702. (Pubitemid 43964625)
3. McCrone P, Heslin M, Knapp M, et al. Multiple sclerosis in the UK. Pharmacoeconomics. 2008;26:847-60.
4. Ryan M, Deno S, Zwibel H. Review of the clinical debate regarding interventions for multiple sclerosis. J Manag Care Pharm. 2009;15:S1-17.
5. Boggild M, Palace J, Barton P, et al. Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator. Br Med J. 2009;339:1359-63.
6. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in the United Kingdom. Eur J Health Econ. 2006;7(Suppl 2):S96-104.
7. Orme M, Kerrigan J, Tyas D, et al. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health. 2007;10:54-60. (Pubitemid 46161095)
8. Chilcott J, McCabe C, Tappenden P, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. BMJ. 2003;326:522-8.
9. Naci H, Fleurence R, Birt J, et al. The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature. J Med Econ. 2010;13:78-89.
10. Phillips C, Humphreys I. Assessing cost-effectiveness in the management of multiple sclerosis. ClinicoEcon Outcomes Res. 2009;1:61-78.
11. National Institute for Clinical Excellence. Beta interferon and glatiramer acetate for the treatment of multiple sclerosis. Guidance No. 32; 2002.
12. National Institute for Health and Clinical Excellence. Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis. Guidance No. TA127. London: National Institute for Health and Clinical Excellence; 2007.
13. McCabe C, Chilcott J, Claxton K, et al. Continuing the multiple sclerosis risk sharing scheme is unjustified. BMJ (Clinical research ed). 2010;340:c1786.
14. National Institute for Health and Clinical Excellence. Fingolimod for the treatment of highly active relapsing-remitting multiple sclerosis. TA254; 2012.
15. Holmoy T, Gulowsen Celius E. Cost-effectiveness of natalizumab in multiple sclerosis. Expert Rev Pharmacoecon Outcomes Res. 2008;8:11-21. (Pubitemid 351377270)
16. Bryant J, Clegg A, Milne R. Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on effectiveness and cost? J Neurol Neurosurg Psychiatry. 2001;70:574-9. (Pubitemid 32397991)
17. Phillips C. The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment. CNS Drugs. 2004;18:561-74. (Pubitemid 38951779)
18. Sharac J, McCrone P, Sabes-Figuera R. Pharmacoeconomic considerations in the treatment of multiple sclerosis. Drugs. 2010;70:1677-91.
19. Hoch J. Cost-effectiveness lessons from disease-modifying drugs in the treatment of multiple sclerosis. Expert Rev Pharmacoecon Outcomes Res. 2004;4:537-47. (Pubitemid 39359640)
20. Chiao E, Meyer K. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis. Curr Med Res Opin. 2009;25:1445-54.
21. Bakhshai J, Bleu-Laine R, Jung M, et al. The cost effectiveness and budget impact of natalizumab for formulary inclusion. J Med Econ. 2010;13:63-9.
22. Earnshaw S, Graham J, Oleen-Burkey M, et al. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis. Appl Health Econ Health Policy. 2009;7:91-108.
23. Gani R, Giovannoni G, Bates D, et al. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis. Pharmacoeconomics. 2008;26:617-27. (Pubitemid 351876727)
24. Kobelt G, Berg J, Lindgren P, et al. Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden. Mult Scler. 2008;14:679-90. (Pubitemid 351954411)
25. O'Day K, Meyer K, Miller R, et al. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis. J Med Econ. 2011;14:617-27.
26. Noyes K, Bajorska A, Chappel A, et al. Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population based study. Neurology. 2011;77:353-63.
27. Becker R, Dembeck C. Effects of cohort selection on the results of cost-effectiveness analysis of disease-modifying drugs for relapsing-remitting multiple sclerosis. J Manag Care Pharm. 2011;17:377-81.
28. Nuijten M, Mittendorf T. A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective. Clin Ther. 2010;32:717-28.
29. Tappenden P, McCabe C, Chilcott J, et al. Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population. Value Health. 2009;12:657-65.
30. Goldberg L, Edwards N, Fincher C, et al. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm. 2009;15:543-55.
31. Castelli-Haley J, Oleen-Burkey M-KA, Lage M, et al. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients. Adv Ther. 2008;25:658-73.
32. Bell C, Graham J, Earnshaw S, et al. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm. 2007;13:245-61. (Pubitemid 46730893)
33. Prosser L, Kuntz K, Bar-Or A, et al. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health. 2004;7:554-68. (Pubitemid 39390836)
34. Bose U, Kadkhani D, Burrell A, et al. Cost-effectiveness analysis of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. J Drug Assess. 2002;5:67-79.
35. Guo S, Bozkaya D, Ward A, et al. Treating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon beta-1a: modelling the clinical and economic implications. Pharmacoeconomics. 2009;27:39-53.
36. Iskedjian M, Walker J, Gray T, et al. Economic evaluation of Avonex (interferon beta-1a) in patients following a single demyelinating event. Mult Scler. 2005;11:542-51. (Pubitemid 41387699)
37. Lepen C, Coyle P, Vollmer T, et al. Long-term cost-effectiveness of interferon-β-1a in the treatment of relapsing-remitting multiple sclerosis. Clin Drug Investig. 2003;23:571-81. (Pubitemid 37115073)
38. Touchette D, Durgin T, Wanke L, et al. A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis. Clin Ther. 2003;25:611-34. (Pubitemid 36286924)
39. Kobelt G, Jönsson L, Fredrikson S. Cost-utility of interferon β1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis. Eur J Health Econ. 2003;4:50-9. (Pubitemid 36457057)
40. Lazzaro C, Bianchi C, Peracino L, et al. Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon beta-1b. Neurol Sci. 2009;30:21-31.
41. Kobelt G, Jönsson L, Miltenburger C, et al. Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis using natural history data. Int J Technol Assess Health Care. 2002;18:127-38. (Pubitemid 34408535)
42. Nuijten M, Hutton J. Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis. Value Health. 2002;5:44-54. (Pubitemid 34160370)
43. Phillips C, Gilmour L, Gale R, et al. A cost utility model of interferon beta-1b in the treatment of relapsing-remitting multiple sclerosis. J Med Econ. 2001;4:35-50. (Pubitemid 32367058)
44. Brown M, Murray T, Sketris I, et al. Cost-effectiveness of interferon beta-1B in slowing multiple sclerosis disability progression. Int J Technol Assess Health Care. 2000;16:751-67.
45. Kendrick M, Johnson K. Long term treatment of multiple sclerosis with interferon-β may be cost effective. Pharmacoeconomics. 2000;18:45-53. (Pubitemid 30468867)
46. Kobelt G, Jönsson L, Henriksson F, et al. Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis. Int J Technol Assess Health Care. 2000;16:768-80.
47. Forbes R, Lees A, Waugh N, et al. Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis. BMJ. 1999;319:1529-33.
48. Parkin D, Jacoby A, McNamee P, et al. Treatment of multiple sclerosis with interferon-β: an appraisal of cost-effectiveness and quality of life. J Neurol Neurosurg Psychiatry. 2000;68:144-9. (Pubitemid 30245835)
49. Tappenden P, Saccardi R, Confavreux C, et al. Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis. Bone Marrow Transpl. 2010;45:1014-21.
50. Kobelt G, Texier-Richard B, Lindgren P. The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions. Mult Scler. 2009;15:741-51.
51. Higginson I, McCrone P, Hart S, et al. Is short-term palliative care cost-effective in multiple sclerosis? A randomized phase II trial. J Pain Symptom Manag. 2009;38:816-26.
52. Pozzilli C, Brunetti M, Amicosante A, et al. Home based management in multiple sclerosis: results of a randomised controlled trial. J Neurol Neurosurg Psychiatry. 2002;73(3):250-5.
53. Curkendall S, Wang C, Hohnson B, et al. Potential health care cost savings associated with early treatment of multiple sclerosis using disease modifying therapy. Clin Ther. 2011;33:914-25.
54. Tan H, Yu J, Tabby D, et al. Clinical and economic impact of a specialty care management program among patients with multiple sclerosis: a cohort study. Mult Scler. 2010;16:956-63.
55. Rajagopalan K, Brook R, Beren I, et al. Comparing the costs and absences for multiple sclerosis among US employees: pre- and post-treatment initiation. Curr Med Res Opin. 2011;27:179-88.
56. Kurtzke J. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444-52. (Pubitemid 14237132)
57. Tappenden P, McCabe C, Simpson E, et al. The clinical effectiveness and cost-effectiveness of interferon-beta and glatiramer acetate in the management of relapsing/remitting and secondary-progressive multiple sclerosis. Maryland, USA: Agency for Healthcare Research and Quality, Department of Health and Human Services; 2006.
58. Prosser L, Kuntz K, Bar-Or A, et al. Patient and community preferences for treatments and health states in multiple sclerosis. Mult Scler. 2003;9:311-9. (Pubitemid 36681901)
59. Henriksson F, Fredrikson S, Masterman T. Cost, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur J Neurol. 2001;8:27-35. (Pubitemid 32154571)
60. Berg J, Lindgren P, Fredrikson S, et al. Costs and quality of life of multiple sclerosis in Sweden. Eur J Health Econ. 2006;7:75-85.
61. Grima DT, Torrance GW, Francis G, et al. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler. 2000;6:91-8. (Pubitemid 30218902)
62. Parkin D, McNamee P, Jacoby A, et al. A cost-utility analysis of interferon beta for multiple sclerosis. Health Technol Assess. 1998;2:1-45. (Pubitemid 28239820)
63. Kobelt G, Lindgren P, Parkin D, et al. Cost and quality of life in multiple sclerosis. A cross-sectional observational study in the UK. Working Paper Series in Economics and Finance. Stockholm: Stockholm School of Economics; 2000.
64. EuroQol Group. EQ-5D user guide. Rotterdam: The EuroQol Group; 1996.
65. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095-108. (Pubitemid 127453463)
66. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21:271-92. (Pubitemid 34143147)
67. Brazier J, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care. 2004;42:851-9. (Pubitemid 39456916)
68. Torrance G, Feeny D, Furlong W, et al. Multi-attribute preference functions for a comprehensive health status classification systems: Health Utilities Index Mark 2. Med Care. 1996;34:702.
69. Ebers GC. Outcome measures were flawed. BMJ. 2010;340:1286.
70. Ebers GC, Heigenhauser L, Daumer M, et al. Disability as an outcome in MS clinical trials. Neurology. 2008;71:624-31.
71. Tyas D, Kerrigan J, Russell N, et al. The distribution of the cost of multiple sclerosis in the UK: How do costs vary by illness severity? Value Health. 2007;10:386-9. (Pubitemid 47481109)
72. Weinshenker B, Bass B, Rice G, et al. The natural history of multiple sclerosis: a geographically based study 1. Clinical course and disability. Brain. 1989;112:133-46. (Pubitemid 19056478)
73. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain. 1993;116:117-34. (Pubitemid 23087038)
74. Tremlett H, Paty DW, Devonshire V. Disability progression in multiple sclerosis is much slower than previously reported. Neurology. 2006;66:172-7. (Pubitemid 43970148)
75. Zajicek J, Freeman J, Porter B. Multiple sclerosis: a practical manual. Oxford: Oxford University Press; 2007.
76. Zajicek J, Ingram W, Vickery J, et al. Patient-orientated longitudinal study of multiple sclerosis in south west England (The South West Impact of Multiple Sclerosis project, SWIMS) 1: Protocol and baseline characteristics of cohort. BMC Neurol. 2010;10:88.
77. Oleen-Burkey M, Castelli-Haley J, Lage M, et al. Burden of a multiple sclerosis relapse. The patient's perspective. Patient. 2012;5:57-69.
78. Parkin D, Jacoby A, McNamee P, et al. Treatment of multiple sclerosis with interferon-β: an appraisal of cost-effectiveness and quality of life. J Neurol Neurosurg Psychiatry. 2000;68:144-9. (Pubitemid 30245835)
79. Patwardhan M, Matchar D, Samsa G, et al. Cost of multiple sclerosis by level of disability: a review of literature. Mult Scler. 2005;11:232-9. (Pubitemid 40403265)
80. Claxton K, Walker S, Palmer S, et al. Appropriate perspectives for health care decisions. CHE Research Paper. York: Centre for Health Economics; 2010.
81. Koopmanschap M, Rutten FFH, Vanineveld B, et al. The friction cost method for measuring indirect costs of disease. J Health Econ. 1995;14:171-89.
82. Anderson R. Systematic reviews of economic evaluations: utility or futility? Health Econ. 2010;19:350-64.
83. Saramago P, Manca A, Sutton A. Deriving input parameters for cost-effectiveness modeling: taxonomy of data types and approaches to their statistical synthesis. Value Health. 2012;15:639-49.
84. Ara R, Wailoo A. Using health state utility values in models exploring the cost-effectiveness of health technologies. Value Health. 2012;15(6):971-4.
85. Ford D, Jones K, Middleton R, et al. The feasibility of collecting information from people with Multiple Sclerosis for the UK MS Register via a web portal: characterising a cohort of people with MS. BMC Med Inf Decis Mak. 2012;12:73.